Navigation Links
Hillenbrand Releases Investor Roadshow Materials and Updated Financial Guidance Related to Separation Of Hill-Rom and Batesville Casket
Date:3/13/2008

lts could differ materially from those set forth in any forward- looking statements.

Factors that could cause Hill-Rom's actual results to differ from forward- looking statements include but are not limited to: Hill-Rom's dependence on its relationships with several large group purchasing organizations, whether Hill-Rom's new products are successful in the marketplace, changes in customers' Medicare reimbursements, collections of accounts receivable, compliance with FDA regulations, antitrust litigation, potential exposure to product liability or other claims, failure of Hill-Rom's announced strategic initiatives and restructuring and realignment activities to achieve expected growth, efficiencies or cost reductions, disruptions in Hill-Rom's business or other adverse consequences resulting from the planned separation of Hillenbrand's two operating companies, failure to realize the anticipated benefits of the separation, failure of Hill-Rom to execute its acquisition and business alliance strategy through the consummation and successful integration of acquisitions or entry into joint ventures or other business alliances, increased costs or unavailability of raw materials, labor disruptions, the ability to retain executive officers and other key personnel, and certain tax- related matters. For a more in depth discussion of these and other factors that could cause Hill-Rom's actual results to differ from those contained in forward-looking statements, see the discussions under the heading "Risk Factors" in Hillenbrand's Annual Report on Form 10-K for the period ended September 30, 2007.

Factors that could cause Batesville's actual results to differ from forward-looking statements include but are not limited to: Batesville's dependence on its relationships with several large national providers, changes in death rates, whether Batesville's new products are successful in the marketplace, antitrust litigation, potential exposure to product liability or other
'/>"/>

SOURCE Hillenbrand Industries, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Hillenbrand Industries Announces Fourth Quarter 2007 Dividend
2. Hillenbrand Industries Announces Second Quarter 2008 Dividend
3. Hillenbrand Announces Mailing of Proxy Regarding Changing of Company Name in Conjunction with Planned Separation
4. Hillenbrand Industries, Inc. Announces Any and All Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009
5. Cleveland Clinic Press Releases Journal-Writing Book Write for Life: Healing Body, Mind, and Spirit Through Journal Writing by Sheppard B. Kominars, Ph.D.
6. Leading Child Abuse Center Releases Back to School Tips to Protect Children From Internet Predators
7. JHA Releases 2007 U.S. Group Disability Mid-Year Market Survey Results
8. Verdict One Releases Directory of Board Certified Attorneys for Consumers
9. Academy releases emergency preparedness tools to enable millions more people to shelter in place
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. MITEM Releases Blue Iris eLaborate 8.6
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... research, published in the journal Oncotarget , ... different appearances or their own DNA signatures within ... difficult to design effective, targeted treatment strategies. , ... EGFR mutation and either the KRAS or BRAF ... by the EGFR gene mutation have that specific ...
(Date:4/22/2014)... is a popular high school sport in the United ... study by researchers in the Center for Injury Research ... to compare and describe the occurrence and distribution patterns ... high school athletic training setting among adolescents and teens. ... of Athletic Training , examined data relating to adolescents ...
(Date:4/22/2014)... Health clinics that can provide primary care for ... both hospitals and insurance companies while improving patient ... hospital admissions suggests that health clinics that avoid ... save money by lowering hospital admission rates and ... of economics, Penn State Altoona. , The ...
(Date:4/22/2014)... 2014: The Association for Molecular Pathology (AMP) released ... Molecular Diagnostics on recommendations for a molecular ... levels of education. The report was prepared by ... of the AMP Training and Education Committee. "Our ... educating future medical laboratory scientists appropriately in order ...
(Date:4/22/2014)... is available in German . ... intracellular signaling molecules, but their mode of action is ... cellular function and behavior, while at high concentrations they ... DNA. To analyze how redox signaling unfolds in single ... technique has been developed jointly by the teams of ...
Breaking Medicine News(10 mins):Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:Neuroimaging: Live from inside the cell 2
... FairWarning, Inc. a provider of healthcare privacy auditing ... titled Addressing Electronic Health Record Privacy ... The Webinar will feature John Wade, ... Robert Sullivan of PricewaterhouseCoopers, Healthcare Advisory ...
... Tour Shows Dramatic Impact of AIDS on Children, ... Funds for Social Causes, CINCINNATI, Feb. 13 ... Network (TPN), has partnered with World,Vision to produce ... a national tour designed to raise awareness about ...
... Monitoring Committee holds third meeting -, ... Life Sciences,Inc. (TSX: BNC), a research-based, technology-driven ... update on the progress,of its North American ... - trademarked Urocidin - in patients with ...
... Most Fertile ... Throughout Entire Month, PRINCETON, N.J., Feb. 13 Trying to predict ... provide,only a handful of chances to identify the two most fertile days ... most fertile,days: The new FIRST RESPONSE Daily Ovulation Test includes 20 testing,sticks ...
... for heart, pneumonia care, ST. PAUL, Minn., Feb. ... metro area in three key areas of a,national quality ... heart attack, heart failure and pneumonia care, according to,The ... "We,re very proud of the ongoing quality improvement work ...
... GARDENA, Calif., Feb. 13 Consumers today are ... away from,carbs, while other experts say that the ... we take in each day. The answers may ... oldest populations on earth, namely,Japan., Zojirushi ( ...
Cached Medicine News:Health News:FairWarning to Host Webinar Featuring HIMSS Chairman and Healthcare Executive from PricewaterhouseCoopers on Electronic Health Record Privacy and Compliance Challenges 2Health News:The Brand Experience Teams With World Vision to Launch 'Experience: AIDS' Multi-Media Exhibit 2Health News:The Brand Experience Teams With World Vision to Launch 'Experience: AIDS' Multi-Media Exhibit 3Health News:Bioniche Provides Update on Refractory Bladder Cancer Trial with Urocidin(TM) 2Health News:Bioniche Provides Update on Refractory Bladder Cancer Trial with Urocidin(TM) 3Health News:New FIRST RESPONSE(R) Home Ovulation Test Takes the Guesswork Out of Conception 2Health News:Busting the Myth, One Bowl at a Time 2
(Date:1/15/2014)... IRVING, Texas , Jan. 15, 2014  Novation, the ... company, awarded several new IT value-added reseller (VAR) national ... with IT goods and services at lower costs. These ... value-added services such as initiative assistance and ongoing IT ...
(Date:1/15/2014)... 2014 Massachusetts General Hospital (MGH), the Broad ... announced today that they have launched a strategic ... targets and develop novel therapies for inflammatory bowel ... worldwide. The MGH-Broad-Amgen collaboration brings together scientists with ...
(Date:1/15/2014)... FORT WORTH, Texas , Jan. 15, 2014  Humberto ... in Dermatology Achievement Award" from the Journal of ... Dermatology Aesthetic & Clinical Conference (ODAC). The event is January ... Florida . The ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... 17 Innocoll, Inc., a privately-held,biopharmaceutical company, ... phase,2 clinical trials sponsored by its wholly ... GENTAMICIN TOPICAL for the,treatment and prevention of ... GENTAMICIN TOPICAL is a biodegradable and fully ...
... Biosciences,Incorporated (Nasdaq: KOSN ) presented preclinical data ... in vitro and in vivo,activity as well as ... NEI anticancer mechanism of action correlating inhibition,of the ... cancer cells,compared to normal cells. Data on Kosan,s ...
Cached Medicine Technology:Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 2Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 3Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 4Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 2Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 3Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 4
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
For use with catalog #0540....
Determination of FDP in Plasma by Latex Agglutination, 60 tests.Microlatex particles coated with mouse monoclonal anti-human FDP antibodies....
Medicine Products: